Back to Menu
Cholangiocarcinoma is a malignant tumor originating from the biliary epithelium and is classified as intrahepatic or extrahepatic, with geographic variation in incidence. It is highly invasive and prone to metastasis, and obstructive jaundice is a hallmark clinical feature.
1. Intrahepatic cholangiocarcinoma
Arises from intrahepatic bile duct epithelium and accounts for approximately 10%–20% of cases. It is often asymptomatic at an early stage, and most patients present with advanced disease and poor prognosis.
2. Perihilar cholangiocarcinoma
Also known as a Klatskin tumor, accounting for approximately 50%–60% of cases. It frequently involves hilar vasculature, making surgery technically demanding.
3. Distal cholangiocarcinoma
Arises from the distal extrahepatic bile duct and accounts for approximately 20%–30% of cases. Obstructive jaundice predominates, and resectability is relatively higher.
4. Histopathological classification
Adenocarcinoma accounts for >90% of cases and is graded as well-, moderately, or poorly differentiated; degree of differentiation is closely associated with prognosis.
1. Biliary tract diseases
Primary sclerosing cholangitis is a major risk factor; choledochal cysts and cholelithiasis are also closely associated.
2. Liver fluke infection
Clonorchis sinensis infection is an important risk factor in high-incidence regions, particularly in parts of Southeast Asia, and promotes chronic inflammation.
3. Metabolic and genetic factors
Obesity and diabetes increase risk. Lynch syndrome and BRCA1/2 mutations are associated with susceptibility.
4. Environmental and lifestyle factors
Long-term exposure to asbestos and dioxins may increase risk; smoking and heavy alcohol use may act synergistically in tumorigenesis.
5. Viral hepatitis
Chronic hepatitis B and C infections are associated with increased risk of intrahepatic cholangiocarcinoma and may promote malignant transformation.
1. Avoid risk factors
Prevent biliary parasite infection, avoid exposure to chemical carcinogens, maintain healthy body weight, and manage metabolic disorders.
2. Management of chronic biliary disease
Actively treat primary sclerosing cholangitis and choledochal cysts, with regular surveillance to enable early detection.
3. Healthy dietary habits
Increase intake of fruits and vegetables, reduce processed meats, maintain a balanced diet, and control caloric intake to reduce obesity-related risk.
4. Regular screening and monitoring
High-risk populations should undergo periodic ultrasonography and MRCP. Prompt evaluation is recommended when suspicious symptoms occur.
5. Genetic counseling and testing
Individuals with a family history should consider genetic counseling to assess individual risk and develop personalized preventive strategies.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that cholangiocarcinoma is highly malignant, diagnostically complex, and life-threatening. Early diagnosis and standardized treatment are key to improving cure rates. MDT-based collaboration and emerging therapies such as targeted and immunotherapy continue to improve outcomes. The public should understand risk factors, high-risk individuals should undergo regular screening, maintain healthy lifestyle practices, and seek timely medical evaluation when symptoms occur.
Cholangiocarcinoma is a malignant tumor originating from the biliary epithelium and is classified as intrahepatic or extrahepatic, with geographic variation in incidence. It is highly invasive and prone to metastasis, and obstructive jaundice is a hallmark clinical feature.
1. Intrahepatic cholangiocarcinoma
Arises from intrahepatic bile duct epithelium and accounts for approximately 10%–20% of cases. It is often asymptomatic at an early stage, and most patients present with advanced disease and poor prognosis.
2. Perihilar cholangiocarcinoma
Also known as a Klatskin tumor, accounting for approximately 50%–60% of cases. It frequently involves hilar vasculature, making surgery technically demanding.
3. Distal cholangiocarcinoma
Arises from the distal extrahepatic bile duct and accounts for approximately 20%–30% of cases. Obstructive jaundice predominates, and resectability is relatively higher.
4. Histopathological classification
Adenocarcinoma accounts for >90% of cases and is graded as well-, moderately, or poorly differentiated; degree of differentiation is closely associated with prognosis.
1. Biliary tract diseases
Primary sclerosing cholangitis is a major risk factor; choledochal cysts and cholelithiasis are also closely associated.
2. Liver fluke infection
Clonorchis sinensis infection is an important risk factor in high-incidence regions, particularly in parts of Southeast Asia, and promotes chronic inflammation.
3. Metabolic and genetic factors
Obesity and diabetes increase risk. Lynch syndrome and BRCA1/2 mutations are associated with susceptibility.
4. Environmental and lifestyle factors
Long-term exposure to asbestos and dioxins may increase risk; smoking and heavy alcohol use may act synergistically in tumorigenesis.
5. Viral hepatitis
Chronic hepatitis B and C infections are associated with increased risk of intrahepatic cholangiocarcinoma and may promote malignant transformation.
1. Avoid risk factors
Prevent biliary parasite infection, avoid exposure to chemical carcinogens, maintain healthy body weight, and manage metabolic disorders.
2. Management of chronic biliary disease
Actively treat primary sclerosing cholangitis and choledochal cysts, with regular surveillance to enable early detection.
3. Healthy dietary habits
Increase intake of fruits and vegetables, reduce processed meats, maintain a balanced diet, and control caloric intake to reduce obesity-related risk.
4. Regular screening and monitoring
High-risk populations should undergo periodic ultrasonography and MRCP. Prompt evaluation is recommended when suspicious symptoms occur.
5. Genetic counseling and testing
Individuals with a family history should consider genetic counseling to assess individual risk and develop personalized preventive strategies.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that cholangiocarcinoma is highly malignant, diagnostically complex, and life-threatening. Early diagnosis and standardized treatment are key to improving cure rates. MDT-based collaboration and emerging therapies such as targeted and immunotherapy continue to improve outcomes. The public should understand risk factors, high-risk individuals should undergo regular screening, maintain healthy lifestyle practices, and seek timely medical evaluation when symptoms occur.